Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

MinuteCE®
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
0.50 credits 3 episodes
- John Kastelein, MD, PhD
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
0.50 credits 3 episodes
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
MinuteCE®
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
0.50 program credits
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
0.50 program credits
The current state of secondary prevention in high-risk patients
The current state of secondary prevention in high-risk patients
Hyperlipidemia
The current state of secondary prevention in high-risk patients
- Prof. Thomas Lüscher, MD
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
MinuteCE®
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
0.50 program credits
- Azfar Zaman, MD
0.50 program credits